Associate Group Medical Director

Oncology

Dr. Frank A. Scappaticci, MD

Frank A. Scappaticci works in the field of Oncology. He went to medical school at University at Buffalo, School of Medicine and Biomedical Sciences. Frank Scappaticci is also a published doctor. He has 22 publication published. The most recent publication is: Primary stenting in complete aortic occlusion.

Publications

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer.
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing...
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Mechanisms and future directions for angiogenesis-based cancer therapies.
Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine.
Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice.
Altered expression of cytochrome P450 mRNA during chemical-induced hepatocarcinogenesis and following partial hepatectomy.
Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.
New molecular targets and biological therapies in sarcomas.
Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Primary stenting in complete aortic occlusion.
Intrahepatic pseudocyst complicating acute pancreatitis: imaging findings.
32P-postlabeling analysis of binding of the cyclophosphamide metabolite, acrolein, to DNA.
Interaction of the cyclophosphamide metabolite, acrolein, with lactate dehydrogenase-m homolog.
The therapeutic potential of novel antiangiogenic therapies.

Schools

State University of New York At Buffalo

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Education

Stanford University
University at Buffalo, School of Medicine and Biomedical Sciences

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Garrett A. Smith, MD This Doctor is OpenDoctor Recommended.
	Dr. May C. Chen, MD This Doctor is OpenDoctor Recommended.
	Dr. Charalambos I. Andreadis, MD This Doctor is OpenDoctor Recommended.
	Dr. Rupali K. Nabar, MD This Doctor is OpenDoctor Recommended.
	Dr. Lawrence Fong, MD This Doctor is OpenDoctor Recommended.
	Dr. Weiyun Z. Ai, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jennifer L. Caswell, MD
	Dr. Andrei Goga, MD This Doctor is OpenDoctor Recommended.
	Dr. Pamela M. Klein, MD